These compounds not only reduce oxidative damage but also modulate inflammatory pathways, thereby providing a dual mechanism of action that is beneficial for DN treatment
While Lilly has fixed Mounjaros supply issues for the time being, it plans to double its manufacturing capacity by the year end to avoid any such shortages in the future
The 21st century has seen significant progress in GLP-1R agonist research, with liraglutide (exenatide) becoming the first GLP-1R agonist to be approved by the US Food and Drug Administration (FDA) for the treatment of T2DM in 2005 (Jensterle et al., 2022)
Consequently, future studies must employ advanced methodologies, such as transcriptomics and proteomics technologies with high-throughput capabilities, to conduct more precise investigations into the underlying causes of suboptimal reproductive outcomes in patients with PCOS
Only 5% of AAS users reported consulting physicians
Maintenance : 26 mg every 12 weeks